{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:35:34Z","timestamp":1792301734622,"version":"4.4.0"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1097\/ppo.0000000000000214","type":"journal-article","created":{"date-parts":[[2016,10,4]],"date-time":"2016-10-04T12:16:25Z","timestamp":1475583385000},"page":"326-329","source":"Crossref","is-referenced-by-count":15,"title":["Androgen Receptor and Beyond, Targeting Androgen Signaling in Castration-Resistant Prostate Cancer"],"prefix":"10.1097","volume":"22","author":[{"given":"Zachery R.","family":"Reichert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210203","doi-asserted-by":"crossref","first-page":"29584","DOI":"10.1074\/jbc.M703310200","article-title":"Phosphoinositide 3-kinase-independent non-genomic signals transit from the androgen receptor to Akt1 in membrane raft microdomains","volume":"282","author":"Cinar","year":"2007","journal-title":"J Biol Chem"},{"key":"R2-4-20210203","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","article-title":"Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth","volume":"68","author":"Montgomery","year":"2008","journal-title":"Cancer Res"},{"key":"R3-4-20210203","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1158\/0008-5472.CAN-07-5997","article-title":"Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer","volume":"68","author":"Locke","year":"2008","journal-title":"Cancer Res"},{"key":"R4-4-20210203","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Attard","year":"2008","journal-title":"J Clin Oncol"},{"key":"R5-4-20210203","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1158\/1078-0432.CCR-11-0728","article-title":"Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants","volume":"17","author":"Mostaghel","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R6-4-20210203","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.coph.2008.06.004","article-title":"Targeting CYP17: established and novel approaches in prostate cancer","volume":"8","author":"Yap","year":"2008","journal-title":"Curr Opin Pharmacol"},{"key":"R7-4-20210203","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"R8-4-20210203","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"key":"R9-4-20210203","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jsbmb.2012.01.001","article-title":"Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys","volume":"129","author":"Yamaoka","year":"2012","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R10-4-20210203","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1470-2045(15)70027-6","article-title":"Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial","volume":"16","author":"Saad","year":"2015","journal-title":"Lancet Oncol"},{"key":"R11-4-20210203","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1158\/1535-7163.MCT-14-0521","article-title":"Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer","volume":"14","author":"Toren","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"R12-4-20210203","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1021\/jm040202w","article-title":"Novel C-17-heteroaryl steroidal CYP17 inhibitors\/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model","volume":"48","author":"Handratta","year":"2005","journal-title":"J Med Chem"},{"key":"R13-4-20210203","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1158\/1535-7163.MCT-08-0230","article-title":"Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase\/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer","volume":"7","author":"Vasaitis","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"R14-4-20210203","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"key":"R15-4-20210203","doi-asserted-by":"crossref","first-page":"8141","DOI":"10.1158\/0008-5472.CAN-09-0919","article-title":"Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens","volume":"69","author":"Waltering","year":"2009","journal-title":"Cancer Res"},{"key":"R16-4-20210203","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nm972","article-title":"Molecular determinants of resistance to antiandrogen therapy","volume":"10","author":"Chen","year":"2004","journal-title":"Nat Med"},{"key":"R17-4-20210203","first-page":"149","article-title":"Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome","volume":"63","author":"Hara","year":"2003","journal-title":"Cancer Res"},{"key":"R19-4-20210203","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJM199505253322101","article-title":"Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer","volume":"332","author":"Taplin","year":"1995","journal-title":"N Engl J Med"},{"key":"R20-4-20210203","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/0960-0760(93)90313-L","article-title":"Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors","volume":"46","author":"Berrevoets","year":"1993","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R21-4-20210203","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1158\/1078-0432.CCR-14-1220","article-title":"Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors","volume":"21","author":"Chen","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R22-4-20210203","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0090-4295(01)01010-X","article-title":"Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235)","volume":"58","author":"Kucuk","year":"2001","journal-title":"Urology"},{"key":"R23-4-20210203","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"key":"R24-4-20210203","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"R25-4-20210203","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"R26-4-20210203","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/0008-5472.CAN-11-3948","article-title":"ARN-509: a novel antiandrogen for prostate cancer treatment","volume":"72","author":"Clegg","year":"2012","journal-title":"Cancer Res"},{"key":"R27-4-20210203","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1200\/JCO.2013.50.1684","article-title":"Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer","volume":"31","author":"Rathkopf","year":"2013","journal-title":"J Clin Oncol"},{"key":"R28-4-20210203","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1158\/1535-7163.MCT-12-1174","article-title":"AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo","volume":"12","author":"Loddick","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"R29-4-20210203","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s10637-015-0235-5","article-title":"AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer\u2014results of two parallel first-in-human phase I studies","volume":"33","author":"Omlin","year":"2015","journal-title":"Invest New Drugs"},{"key":"R30-4-20210203","doi-asserted-by":"crossref","first-page":"12007","DOI":"10.1038\/srep12007","article-title":"Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling\u2013directed prostate cancer therapies","volume":"5","author":"Moilanen","year":"2015","journal-title":"Sci Rep"},{"key":"R31-4-20210203","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1158\/1535-7163.MCT-11-0329","article-title":"Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer","volume":"10","author":"Zhang","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"R32-4-20210203","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1038\/bjc.2013.619","article-title":"First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer","volume":"109","author":"Bianchini","year":"2013","journal-title":"Br J Cancer"},{"key":"R33-4-20210203","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1158\/0008-5472.CAN-11-3892","article-title":"Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer","volume":"72","author":"Hu","year":"2012","journal-title":"Cancer Res"},{"key":"R34-4-20210203","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"key":"R35-4-20210203","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ccr.2010.04.027","article-title":"Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor","volume":"17","author":"Andersen","year":"2010","journal-title":"Cancer Cell"},{"key":"R36-4-20210203","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1172\/JCI66398","article-title":"An androgen receptor N-terminal domain antagonist for treating prostate cancer","volume":"123","author":"Myung","year":"2013","journal-title":"J Clin Invest"},{"key":"R37-4-20210203","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/pros.22504","article-title":"Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer","volume":"72","author":"Isaacs","year":"2012","journal-title":"Prostate"},{"key":"R38-4-20210203","doi-asserted-by":"crossref","first-page":"269ra2","DOI":"10.1126\/scitranslmed.3010563","article-title":"Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study","volume":"7","author":"Schweizer","year":"2015","journal-title":"Sci Transl Med"},{"key":"R39-4-20210203","doi-asserted-by":"crossref","first-page":"35542","DOI":"10.18632\/oncotarget.4689","article-title":"Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer","volume":"6","author":"Perner","year":"2015","journal-title":"Oncotarget"},{"key":"R40-4-20210203","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/jcp.25099","article-title":"Androgen receptor coactivators in regulation of growth and differentiation in prostate cancer","volume":"231","author":"Culig","year":"2016","journal-title":"J Cell Physiol"},{"key":"R41-4-20210203","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.molonc.2015.02.010","article-title":"Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells \u2192 androgen receptor (AR) \u2192 miRNA32 signal","volume":"9","author":"Dang","year":"2015","journal-title":"Mol Oncol"},{"key":"R42-4-20210203","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000214","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:22:36Z","timestamp":1620969756000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00130404-201609000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000214","relation":{},"ISSN":["1528-9117"],"issn-type":[{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]}}}